Control infant formula
OtherAd libitum or as instructed by HCP, feeding period from enrollment to 12 months of age
NCT Number: NCT04957992
The purpose of this study is to evaluate the growth and development outcomes of infants fed a new infant formula and toddler drink through 24 months of age.
Looking for future studies?
Notify Me0 day–14 day
All sexes
Interventional
Not applicable
MedPharmics, LLC 3192, Phoenix, Arizona, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Ad libitum or as instructed by HCP, feeding period from enrollment to 12 months of age
~ 16 fl oz per day as primary milk beverage; feeding period from 12 to 24 months of age
Ad libitum or as instructed by HCP, feeding period from enrollment to 12 months of age
~ 16 fl oz per day as primary milk beverage; feeding period from 12 to 24 months of age
Ad libitum or as instructed by HCP
Ad libitum if consuming supplemented formula; feeding period up to 12 months of age
~16 fl oz per day if providing supplemental nutrition other than HM; feeding period from 12 to 24 months of age
Time frame: Study Day 1 to 6 Months of Age
weight for age z-score
Time frame: Study Day 1 to 24 Months of Age
Adverse event reports
Time frame: Study Day 1 to 24 Months of Age
Adverse event reports
Time frame: Study Day 1 to 24 Months of Age
Adverse event reports
Time frame: Study Day 1 to 24 Months of Age
Adverse event reports
Time frame: Study Day 1 to 24 Months of Age
Interval weight gain per day
Time frame: Study Day 1 to 24 Months of Age
Interval length gain per day
Time frame: Study Day 1 to 24 Months of Age
Interval head circumference gain per day
Time frame: Study Day 1 to 12 months of Age
Parent completed diary
Time frame: 28 Days of Age to 6 Months of Age
Parent completed questionnaire; 12 questions with 5-point Likert scale questions scaled from positive to negative
Time frame: 18 Months of Age to 24 Months of Age
Parent completed questionnaire; 12 questions with 5-point Likert scale questions scaled from positive to negative
Time frame: 28 Days of Age to 119 Days of Age]
Parent completed questionnaire; 16, 5-point Likert scale questions, scaled from Always to Never
Time frame: 119 Days of Age
Parent completed questionnaire; 22 questions with 5-point Likert scale questions, scaled from Always to Never
Time frame: Study Day 1 to 24 Months of Age
Parent completed intake diary
Time frame: 6 Months of Age to 24 Months of Age
Parent completed 24-hour recall
Time frame: Study Day 1 to 24 Months of Age
Microbiota characterization; Subset of subjects
Time frame: 12 Months of Age to 24 Months of Age
Examiner rated assessment; Scores are totaled and compared to normative age group data and between groups; Subset of subjects
Time frame: 12 Months of Age to 24 Months of Age
Parent completed questionnaire of Words and Gestures and Words and Sentences; Percentiles compared to normative group data and between groups
Time frame: 6 Months of Age to 24 Months of Age]
Parent completed questionnaire; 8 questions related to the home environment adapted from the HSF compared between groups
Time frame: Study Day 1 to 24 Months of Age
Medication usage including frequency and reason for use
Time frame: Study Day 1 to 24 Months of Age
Parent reported adverse events
Time frame: Study Day 1 to 24 Months of Age
Number of visits
Time frame: Study Day 1 to 24 Months of Age
Parent reported number of days
Time frame: 6 and 24 Months of Age
Blood Immune Markers; Subset of subjects
Abbott Nutrition
Industry
Infant Formula and Toddler Drink Feeding Intervention Through 24 Months of Age
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06312059
Growth
New York, United States
View Trial DetailsNCT04316221
Development; Delayed, Growth
Tecpán Guatemala, Departamento de Chimaltenango, Guatemala
View Trial DetailsNCT07302477
Adverse Event, Growth
Chak Four Hundred Fifty-four, Pakistan
View Trial DetailsNCT07296718
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Feeding Intolerance
Bahawalpur, Punjab Province, Pakistan
View Trial Details